Brainsway Deep TMS add-on treatment for intractable Tourette syndrome: A feasibility study
Bloch, Y., Arad, S., & Levkovitz, Y. (2014). World Journal of Biological Psychiatry, (Epub ahead of print).
This study explores the effect of Brainsway® Deep TMS (Transcranial Magnetic Stimulation) on adults who suffer from intractable Tourette Syndrome (TS). The study enrolled 12 patients and was held over 20 days. The study found no significant side effects, and indicated that Deep TMS is safe for treating TS. In the study, the subgroup who suffered from both TS and Obsessive Compulsive Disorder (OCD) experienced significant improvement - a beneficial result that also indicates that TS is not of a uniform nature.
Brainsway's international website includes clinical and regulatory data for indications which were not cleared by the FDA for use in the United States.
This site is not intended for residents of the United States, its territories, and Puerto Rico.
The FDA cleared Brainsway's Deep TMS system for use in the U.S for treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode.
Would you like to proceed to the international website? To proceed click here
or click here to close this window